Trial Profile
Phase 2 Trial of Ixazomib Combinations in Patients With Relapsed Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Cyclophosphamide; Daratumumab; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Feb 2023 Planned End Date changed from 1 Sep 2023 to 1 Feb 2026.
- 01 Feb 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Feb 2026.
- 25 Oct 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Jan 2023.